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Summary: A study is reported on the determination of creatinine with the DuPont Dimension, paying special
attention to interference by bilirubin. Various methods for dealing with bilirubin interference are described,
including modification of the Jaffe reaction, enzymatic assay of creatinine, enzymatic destruction of bilirubin,
and ultrafiltration of the serum sample. None of these modifications gave completely satisfactory results,
although the Jaffe method with a ferricyanide oxidation step, and the enzymatic assay with ferrocyanide gave
reasonable results with icteric specimens from adult patients, while only the latter method could be used for
neonatal serum samples.
Introduction
Recently we described our concern about the accuracy
of the determination of creatinine in serum, especially
in icteric specimens (1). We also mentioned the co-
operation of the Bayer-Technicon company and the
DuPont company. The cooperation with the first,
needed because the Chem-1 is a closed system, re-
sulted in preliminary data (2). Regarding the coop-
eration with DuPont, we were able to work more
independently because of the open channel facility in
the Dimension. Therefore we decided to continue the
Dimension study by evaluating some modifications
of creatinine methods described in the literature to
circumvent or at least diminish the influence of bili-
rubin.
We tested the following approaches:
1. A kinetic Jaffe method incorporating a ferricya-
nide oxidation step to minimise the bilirubin infer-
ference (3).
2. A kinetic Jaffe method including a pre-incubation
with bilirubin oxidase (EC 1.3.3.5) (4).
3. An enzymatic procedure employing creatininase
(EC 3.5.2.10) and creatinase (EC 3.5.3.3) as eval-
uated by Glider et al. (5) with the inclusion of
potassium ferrocyanide to minimise the interfer-
ence from bilirubin in the measurement of hydro-
gen peroxide (6).
4. The creatininase/creatinase procedure (as de-
scribed under 3), but with pre-incubation with bil-
irubin oxidase instead of inclusion of potassium
ferrocyanide (7).
5. Ultrafiltration of the serum sample and measure-
ment of the ultrafiltrate with the current Dimen-
sion procedure which is a kinetic Jaffe method (8).
DuPont provided an experimental Flex™ reagent
cartridge, which they are developing for the ferri-
cyanide oxidation step. They also provided prelim-
inary software. The other approaches were studied
with empty Flex™ cartridges, using our own rea-
gents.
Materials and Methods
Materials
Creatinine, unconjugated bilirubin and potassium ferrocyanide
(K4Fe(CN)6) were from Merck (Germany); conjugated bilirubin
(ditaurate, di Na) from Porphyrin Products Inc. (Logan, Utah,
U.S.A.); bilirubin oxidase (EC 1.3.3.5) from Sigma (St. Louis,
U. S. A.) and human albumin from Behring Werke (Germany).
Methods
1. A special creatinine Flex™ cartridge, called XCREA, and
containing potassium ferricyanide (K3Fe(CN)6), was pre-
pared by DuPonl for addition to the NaOH reagent wells.
A separate software pad was developed for initiation of the
reaction cycle.
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2. The pre-incubation with bilirubin oxidase was performed
for 5 minutes, according to the instructions in the product
sheet.
3. Creatinine was determined kinetically with the Test-Com-
bination, Creatinine PAP from Boehringer Mannheim (cat.
No. 839434). Extra potassium ferrocyanide was included in
the bufler/chromogen reagent: 8 mg K4Fe(CN)6 per 20 ml
buffer/chromogen solution.
4. Ultrafiltration was performed with the Centrisart-ί system
from Sartorius (Germany), using a centrifuge with a swing-
head rotor (10-15 min at 2900 #).
5. Interference experiments were done as described previously
(D-
6. Reference mathod: see Zwang et al. (11).
Inst rumentat ion
The DuPont Dimension (DuPont, U. S. A.) was operated ac-
cording to the manufacturer's instructions, except that the
calibration was based on the values obtained for patient samples
run beforehand an the laboratory routine (Chem-1). This cali-
bration procedure is standard in our laboratory though not
recommended by DuPont. However, the differencies between
both procedures are very small in our experience: 3—4% at
elevated creatinine concentrations.
Pat ient samples
An elevated total bilirubin concentration was the only inclusion
criterion for the study. A total of 175 serum samples was
analysed in the first part. For the distribution of the bilirubin
concentrations see table 1.
Tab. 1. Frequency distribution of the total bilirubin concentra-
tions
Concentration range
(μπιοΐ/ΐ)
Number of samples
101-150
151-200
201-250
251-300
301-350
351-400
401-450
451-500
>500
20
42
27
14
18
14
12
8
20
The sera were stored at — 80 °C until analysis (up to 4—6
weeks).
All except four of the analysed neonatal sera (n = 28) were
pooled sera. They were also stored at — 80 °C until analysis
(up to 10 — 12 months).
Results
We started the study by analysing human albumin-
containing creatinine standard solutions enriched with
unconjucated bilirubin (1). This was done at three
creatinine concentrations: ±100, ± 300 and ± 500
μηιοΐ/ΐ. In figure 1 only the results of the lowest
concentration are depicted. The other two concentra-
tions show a comparable picture.
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Fig. 1 The influence of unconjugated bilirubin (spiked human
albumin solutions) on the various creatinine procedures.
Ο Jaffe including ferricyanide oxidation
α Jaffe including pre-incubation with bilirubin oxidase
χ Enzymatic including use of ferrocyanide
Δ enzymatic including pre-incubation with bilirubin
oxidase
* current method (Jaffe)
Experiments performed with conjugated bilirubin (di-
taurobilirubin) revealed the same picture as shown in
figure 1.
To test the practicability and accuracy of the results
obtained with the creatinine standards, we continued
the patient sample correlation study with methods 1
and 3 (see Introduction) in conjunction with the cur-
rent Dimension procedure. Because all three methods
were calibrated by comparison with our routine cre-
atinine method, we first analysed 40 non-icteric, non-
haemolytic and non-lipaemic serum samples with cre-
atinine concentrations between 50 and 1200 μπιοΐ/ΐ
(equally distributed) by HPLC as a linearity check.
The regression lines appeared to be nearly equivalent
to the line y = χ (slopes ±3%, intercept 2—10
μιηοΐ/ΐ).
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Fig. 2. Comparison of the current Dimension creatinine for-
mulation (y-axis) and our HPLC-based comparison
method (x-axis).
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Fig. 3. Comparison of the experimental Dimension creatinine
formulation (y-axis) and our HPLC-based comparison
method (x-axis).
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Fig. 4. Comparison of the modified enzymatic Boehringer cre-
atinine procedure (y-axis) and our HPLC-based com-
parison (x-axis).
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Fig. 5. Comparison of the results of the ultra filtered icteric sera
(current Dimension creatinine method) with those ob-
tained with our HPLC-based comparison method (x-
axis).
Statistical data (orthogonal regression procedure)
y = 1.07x + 19.9
n = 37; r = 1.00; sy/x = 4.1 |imol/l
In figures 2, 3 and 4, comparison graphs are given of
the measurements with 136 icteric serum samples. For
clarity of presentation, we used a cut-off concentra-
tion for creatinine of 250 μπιοΐ/ΐ.
Some of these specimens (n = 38) were also measured
after ultrafiltration using aqueous creatinine stan-
dards. The results are plotted in figure 5.
Finally we analysed 28 neonatal icteric serum samples.
The graphs of these comparisons are shown in figures
6, 7 and 8.
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Fig. 6. Comparison of the current Dimension creatinine
method (y-axis) and our HPLC-based comparison
method (x-axis) for 28 neonatal samples (+ = fresh
sample).
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Fig. 7. Comparison of the experimental Dimension creatinine
method (y-axis) and our HPLC-based comparison
method (x-axis) for 28 neonatal samples (+ = fresh
sample).
Discussion
It is clear from figures 1 to 4 that both modifications,
the adapted enzymatic procedure and the experimen-
tal kinetic Jaffe method (XCREA), are improvements
over the current Dimension formulation. Also, as
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Fig. 8. Comparison of the modified enzymatic Boehringer cre-
atinine procedure (y-axis) and our HPLC-based com-
parison method (x-axis) for 28 neonatal samples
(4- = fresh sample).
Tab. 2. Statistical data of the various modifications
Method: orthogonal Deming procedure
The modification numbers refer to those described in
the Introduction
Fig. 9. Residual Creatinine values (current Dimension minus
HPLC) plotted against the total bilirubin results (x-
axis).
Modification Range n r sy/x
Gimol/l)
Current Jaffe 0-1000 175 1.00 12.6
Revised Jaffe 0-1000 175 1.00 12.1
(mod. 1)
Enzymatic 0-1000 175 1.00 10.0
(mod. 3)
Current Jaffe 0-250 136 0.92 11.0
Revised Jaffe 0-250 136 0.95 9.0
(mod. 1)
Enzymatic 0-250 136 0.97 7.3
(mod. 3)
Ultrafiltration 0-300 37 1.00 4.1
(mod. 5)
judged from the statistical parameters, the correlation
coefficient r and the random error sy/x (see tab. 2),
both of these described modifications for dealing with
bilirubin interference appear to have a positive influ-
ence on the accuracy of the average result. On the
other hand, plotting all data in a different way i.e.
the residual creatinine results versus the bilirubin con-
centration, as in figures 9, 10 and 11, the overall
impression seems to be more decisive.
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rninus HPLC) plotted against the total bilirubin results
[x-axis).
ϊ^ών*^ ·>«: ·"
• :':\Γ3Ρ.·:--.^. .··:.. ·. v·.
/'" ·"·.· '· "
3 200 400 600 800 1000
Bilirubin [gmol/l]
T?<»oi^ii'jl ΛΜ·Ι»<Ι f ir»ir»e» x/olitoe tr^\f\/\\f^a>f\ Ri^eVif Ι·«ΓΤΑ»· winiio
Outlying residual results obtained with the enzymatic
method can be understood for most of these results
(creatinine concentrations not given), either because
the Creatinine concentrations are high to very high
(> 500 μηιοΐ/ΐ) and therefore the residuals less
marked, or the interference clearing system is perhaps
insufficient because of the very high bilirubin concen-
trations (> 300 μπιοΐ/ΐ).
HPLC) plotted against the total bilirubin results (x-
axis).
For the other methods i. e. the current and the exper-
imental Jaffe procedure (XCREA), the correlation
between the residual creatinine* values and the biliru-
bin concentrations is less obvious. This makes the
improvement obtained with the experimental method
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more difficult to understand, except by assuming that
other interfering substances also play a role (9). Fur-
thermore, we want to emphasize that we used a pro-
totype Flex, which, in view of the present results, will
probably not be the final configuration.
We plan to extend this part of the study, not only
because we want to collect more patient-oriented in-
formation, but in order to increase the simplicity and
practicability of the method.
For reasons mentioned earlier we decided not to ex-
tend the experiments with bilirubin oxidase. In addi-
tion, this preparation had a limited stability in our
hands, which made the whole procedure very expen-
sive. Possibly a different bilirubin oxidase procedure
would lead to better results and a more practical
procedure.
The interpretation of figures 6, 7 and 8 causes a
different problem. It is clear that the enzymatic pro-
cedure has the best performance while the current
method is the worst. However, there seems to be a
difference in behaviour between the fresh and the
stored samples, especially in the two Jaffe techniques.
The fresh samples (marked +) though limited in
number, form an exception. The other samples, some
of them already brownish in colour, correlate less or
even badly with HPLC, especially in the current pro-
cedure. Although we know that the storage conditions
were in order, we may have asked too much i. e. four
measurements with samples that are difficult to ob-
tain.
Consideration of the figures requires care, not only
because of the limited number of samples but also
because of the range of creatinine values which may
magnify any apparent discrepancy. On the other
hand, this is what is normally seen with neonates:
high bilirubin values and low creatinine.
We conclude that it makes sense to pay more attention
to the enzymatic approach, not only because of the
results we obtained (see figs. 4 and 8), which are
satisfying but not completely satisfactory, but also for
practical reasons. The stability of the reagent we used
is very limited (only one day) which makes the method
very expensive on the Dimension. There are other
modifications on the market which may be worth
testing with or without modification (10).
Our final remark concerns figure 5. The approach of
ultrafiltration has understandably the advantage of
enhanced accuracy. Of course, by applying the right
calibration procedure, the results obtained with this
approach can be equal to those with HPLC. On the
other hand, the method is more time consuming and
more expensive. The analytical system has the facility
for applying the ultrafiltration method, and the de-
cision is in the hands of the user.
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